CD274 and primary biliary cholangitis: Consequently, the FDA restricted the use of atezolizumab as a 1L treatment to patients who were either ineligible for cisplatin-based chemotherapy with high PD-L1 expression (≥5% of immune cells) or those ineligible for any PBC, regardless of PD-L1 status [71].